Sunday, February 12, 2017 2:01:58 AM
The two trials PH and forthcoming LF are basically addressing respectively the LC compensated patients (at high risk of developing decomensation) and the decompensated patients, with multiple dosages being tested, in order to confirm Emricasan safety and efficacy in treating basically the Cirrhotic patients who need it most.
Out of 50M plus patients suffering from Liver Cirrhosis globally due to all etiologies, there are globally at least 5M suffering from decompensated LC and probably 10M suffering from Severe Portal Pressure hence at high risk of developing decompensation. All of them would be potential Emricasan patients
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992331/
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM